BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Information letter on Dacogen® (decitabine): changes regarding instructions for reconstitution and dilution of Dacogen® 50 MG, powder for concentrate for solution for infusion

Active substance: decitabin

The company Janssen is circulating information that the reconstituted solution of Dacogen® must be diluted to a final concentration in the range 0.15 to 1.0 MG/ML in order to comply with the updated Chapter 5.1.10 of the European Pharmacopoeia.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 485KB, File is accessible